Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines - Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi - Books - Elsevier Science Publishing Co Inc - 9780128042175 - March 14, 2016
In case cover and title do not match, the title is correct

Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi
Clinical Trials: Study Design, Endpoints and Biomarkers, Drug Safety, and FDA and ICH Guidelines 2nd edition

Price
$ 95.99
excl. VAT

Ordered from remote warehouse

Expected to be ready for shipping May 26 - 28

Our customers say:

14-day return policy in accordance with European consumer protection law
Top ranking on Trustpilot
Add to your iMusic wish list

896 pages, Approx. 100 illustrations

Media Books     Hardcover Book   (Book with hard spine and cover)
Released March 14, 2016
ISBN13 9780128042175
Publishers Elsevier Science Publishing Co Inc
Pages 896
Dimensions 243 × 201 × 49 mm   ·   1.97 kg

More by Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi

Show all

Mere med samme udgiver

See all of Brody, Tom, PhD (Consultant for Second Genome, Inc. (Crohn's disease), Rigel Pharmaceuticals (platelet disorder), PrimeGen Biotech (stem cell therapy), Regeneron Pharmaceuticals (broadly neutralizing antibodies for HIV), and Biogen IDEC (multiple sclerosi ( e.g. Hardcover Book )